AdCh3NSmut HCV vaccine / GSK - LARVOL DELTA

Co-administration of serologically distinct adenoviral vectors for HCV and HIV-1 prevention (AGW 2016) - "Material and Methods: Thirty-two healthy volunteers were recruited in a Phase-I (EU Fp7 funded) clinical trial and sequentially enrolled into 3 groups: Group 1 (n = 8) received HCV vaccines: AdCh3NSmut1 [2.5x1010 vp] and MVA.NSmut [2x108 pfu] at weeks 0 and 8, respectively. Co-administration of serologically distinct adenoviral vectors encoding HCV and HIV-1 immunogens in a heterologous prime-boost regimen can be safety administered and induce broad and high magnitude T cell responses. This provides a novel strategy for the prevention of multiple pathogens in the same individual."

Biosimilar • Gene Therapies • Hepatitis C Virus • Immunology

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: University of Oxford

New P1 trial • Biosimilar • Hepatitis C Virus • Immunology • Inflammation